727 related articles for article (PubMed ID: 28301270)
1. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.
Hegde NR; Gore MM
Hum Vaccin Immunother; 2017 Jun; 13(6):1-18. PubMed ID: 28301270
[TBL] [Abstract][Full Text] [Related]
2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
3. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
[TBL] [Abstract][Full Text] [Related]
4. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
[TBL] [Abstract][Full Text] [Related]
5. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
[TBL] [Abstract][Full Text] [Related]
6. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
7. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
8. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
11. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.
Wang SY; Cheng XH; Li JX; Li XY; Zhu FC; Liu P
Hum Vaccin Immunother; 2015; 11(6):1418-25. PubMed ID: 25915588
[TBL] [Abstract][Full Text] [Related]
12. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
13. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
14. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
17. A chimeric live attenuated vaccine against Japanese encephalitis.
Jones T
Expert Rev Vaccines; 2004 Jun; 3(3):243-8. PubMed ID: 15176941
[TBL] [Abstract][Full Text] [Related]
18. New Japanese encephalitis vaccines: alternatives to production in mouse brain.
Halstead SB; Thomas SJ
Expert Rev Vaccines; 2011 Mar; 10(3):355-64. PubMed ID: 21434803
[TBL] [Abstract][Full Text] [Related]
19. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Clin Infect Dis; 2013 Jan; 56(2):267-70. PubMed ID: 23074319
[TBL] [Abstract][Full Text] [Related]
20. Development of a recombinant vaccine against Japanese encephalitis.
Kaur R; Vrati S
J Neurovirol; 2003 Aug; 9(4):421-31. PubMed ID: 12907387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
